The correction addresses an error in the article "Integrins in cancer: biological implications and therapeutic opportunities" by Jay S. Desgrosellier and David A. Cheresh, published in *Nature Reviews Cancer* in 2010. Specifically, the sentence regarding the selection of cilengitide as an inhibitor of αvβ3 and αvβ5 integrins was incorrectly phrased. The corrected sentence clarifies that cilengitide was selected through a cell-free receptor assay designed to identify antagonists of αvβ3 and αvβ5 integrins without affecting αIIbβ3. The assay was used to screen a library of integrin-binding cyclic RGD peptides, which were designed and synthesized by H. Kessler and colleagues. The references provided support the selection process and the subsequent findings.The correction addresses an error in the article "Integrins in cancer: biological implications and therapeutic opportunities" by Jay S. Desgrosellier and David A. Cheresh, published in *Nature Reviews Cancer* in 2010. Specifically, the sentence regarding the selection of cilengitide as an inhibitor of αvβ3 and αvβ5 integrins was incorrectly phrased. The corrected sentence clarifies that cilengitide was selected through a cell-free receptor assay designed to identify antagonists of αvβ3 and αvβ5 integrins without affecting αIIbβ3. The assay was used to screen a library of integrin-binding cyclic RGD peptides, which were designed and synthesized by H. Kessler and colleagues. The references provided support the selection process and the subsequent findings.